CA2053187A1 - Production efficace d'une proteine recombinante a l'aide d'un vecteur adenoviral conditionnel sans «helper» - Google Patents
Production efficace d'une proteine recombinante a l'aide d'un vecteur adenoviral conditionnel sans «helper»Info
- Publication number
- CA2053187A1 CA2053187A1 CA 2053187 CA2053187A CA2053187A1 CA 2053187 A1 CA2053187 A1 CA 2053187A1 CA 2053187 CA2053187 CA 2053187 CA 2053187 A CA2053187 A CA 2053187A CA 2053187 A1 CA2053187 A1 CA 2053187A1
- Authority
- CA
- Canada
- Prior art keywords
- expression
- recombinant
- adenovirus
- proteins
- enhancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2053187 CA2053187A1 (fr) | 1991-10-10 | 1991-10-10 | Production efficace d'une proteine recombinante a l'aide d'un vecteur adenoviral conditionnel sans «helper» |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2053187 CA2053187A1 (fr) | 1991-10-10 | 1991-10-10 | Production efficace d'une proteine recombinante a l'aide d'un vecteur adenoviral conditionnel sans «helper» |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2053187A1 true CA2053187A1 (fr) | 1993-04-11 |
Family
ID=4148542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2053187 Abandoned CA2053187A1 (fr) | 1991-10-10 | 1991-10-10 | Production efficace d'une proteine recombinante a l'aide d'un vecteur adenoviral conditionnel sans «helper» |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2053187A1 (fr) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994106A (en) * | 1994-06-10 | 1999-11-30 | Genvec, Inc. | Stocks of recombinant, replication-deficient adenovirus free of replication-competent adenovirus |
US6238893B1 (en) | 1995-06-15 | 2001-05-29 | Introgene B.V. | Method for intracellular DNA amplification |
US6265212B1 (en) | 1995-06-15 | 2001-07-24 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
US6670188B1 (en) | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6783980B2 (en) | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US7846450B2 (en) | 1996-07-11 | 2010-12-07 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Melanoma associated peptide analogues and vaccines against melanoma |
US7989426B2 (en) | 2002-02-15 | 2011-08-02 | Johns Hopkins University School Of Medicine | Selective induction of apoptosis to treat ocular disease by expression of PEDF |
-
1991
- 1991-10-10 CA CA 2053187 patent/CA2053187A1/fr not_active Abandoned
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6482616B1 (en) | 1994-06-10 | 2002-11-19 | Genvec, Inc. | RCA-free adenoviral vector system and propagation method |
US7195896B2 (en) | 1994-06-10 | 2007-03-27 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
US5994106A (en) * | 1994-06-10 | 1999-11-30 | Genvec, Inc. | Stocks of recombinant, replication-deficient adenovirus free of replication-competent adenovirus |
US7105346B2 (en) | 1995-06-15 | 2006-09-12 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6265212B1 (en) | 1995-06-15 | 2001-07-24 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US8236293B2 (en) | 1995-06-15 | 2012-08-07 | Crucell Holland B.V. | Means and methods for nucleic acid delivery vehicle design and nucleic acid transfer |
US6306652B1 (en) | 1995-06-15 | 2001-10-23 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6602706B1 (en) | 1995-06-15 | 2003-08-05 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6395519B1 (en) | 1995-06-15 | 2002-05-28 | Introgene B.V. | Means and methods for nucleic acid delivery vehicle design and nucleic acid transfer |
US6692966B2 (en) | 1995-06-15 | 2004-02-17 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6783980B2 (en) | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6238893B1 (en) | 1995-06-15 | 2001-05-29 | Introgene B.V. | Method for intracellular DNA amplification |
US7052881B2 (en) | 1995-06-15 | 2006-05-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US8075900B2 (en) | 1996-07-11 | 2011-12-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Melanoma associated peptide analogues and vaccines against melanoma |
US7846450B2 (en) | 1996-07-11 | 2010-12-07 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Melanoma associated peptide analogues and vaccines against melanoma |
US6670188B1 (en) | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US7037716B2 (en) | 1998-04-24 | 2006-05-02 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6878549B1 (en) | 1998-04-24 | 2005-04-12 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US7029848B2 (en) | 1998-06-12 | 2006-04-18 | Galapagos Genomics N.V. | High throughput screening of gene function using libraries for functional genomics applications |
US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
US7989426B2 (en) | 2002-02-15 | 2011-08-02 | Johns Hopkins University School Of Medicine | Selective induction of apoptosis to treat ocular disease by expression of PEDF |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5518913A (en) | High level recombinant protein production using conditional helper-free adenovirus vector | |
CA2074502C (fr) | Vaccins | |
Fender et al. | Adenovirus dodecahedron, a new vector for human gene transfer | |
US5770442A (en) | Chimeric adenoviral fiber protein and methods of using same | |
Bett et al. | Packaging capacity and stability of human adenovirus type 5 vectors | |
EP1056881B1 (fr) | Un system simplifie pour la generation d'adenovirus recombinants | |
Schiedner et al. | Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production | |
EP0935648B1 (fr) | Vecteurs d'adenovirus perfectionnes | |
CA2238295C (fr) | Systemes de vecteurs adenoviraux et de lignees cellulaires complementaires | |
EP0704534B1 (fr) | Vecteur ADN viral récombinant pour la transfection de cellules animales | |
US5700470A (en) | Recombinant adenovirus with removed EZA gene and method of preparation | |
US7195896B2 (en) | Complementary adenoviral vector systems and cell lines | |
EP0705344B1 (fr) | Vecteurs a base d'adenovirus destines a la therapie genique | |
US7067309B2 (en) | Defective adenoviruses and corresponding complementation lines | |
US6140087A (en) | Adenovirus vectors for gene therapy | |
JP4733795B2 (ja) | ヒツジアデノウイルスベクターを用いた遺伝子治療 | |
NO321309B1 (no) | Defektive, rekombinante adenovirus, cellelinje, samt et farmasoytisk preparat. | |
CZ230697A3 (en) | Cells for producing recombinant adenoviruses | |
Massie et al. | Improved adenovirus vector provides herpes simplex virus ribonucleotide reductase R1 and R2 subunits very efficiently | |
Loser et al. | Advances in the development of non-human viral DNA-vectors for gene delivery | |
CA2053187A1 (fr) | Production efficace d'une proteine recombinante a l'aide d'un vecteur adenoviral conditionnel sans «helper» | |
JP2003508057A (ja) | 改変アデノウイルスファイバーおよび用途 | |
CA2318737A1 (fr) | Procedes de fabrication de vecteurs pseudo-adenoviraux | |
WO1999053085A2 (fr) | Regulation selective de la production d'adenovirus | |
Gall et al. | Rescue and production of vaccine and therapeutic adenovirus vectors expressing inhibitory transgenes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |